These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7819587)

  • 1. Flow cytometry: potential utility in monitoring drug effects in breast cancer.
    Koester SK; Maenpaa JU; Wiebe VJ; Baker WJ; Wurz GT; Seymour RC; Koehler RE; DeGregorio MW
    Breast Cancer Res Treat; 1994; 32(1):57-65. PubMed ID: 7819587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells.
    Baker WJ; Wiebe VJ; Koester SK; Emshoff VD; Maenpaa JU; Wurz GT; DeGregorio MW
    Breast Cancer Res Treat; 1992; 24(1):43-9. PubMed ID: 1463871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toremifene enhances cell cycle block and growth inhibition by vinblastine in multidrug resistant human breast cancer cells.
    Baker WJ; Maenpaa JU; Wurz GT; Koester SK; Seymour RC; Emshoff VD; Wiebe VJ; DeGregorio MW
    Oncol Res; 1993; 5(6-7):207-12. PubMed ID: 8123940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells.
    Wiebe V; Koester S; Lindberg M; Emshoff V; Baker J; Wurz G; DeGregorio M
    Invest New Drugs; 1992 Jul; 10(2):63-71. PubMed ID: 1386843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bioassay for antiestrogenic activity--potential utility in drug development and monitoring effective in vivo dosing.
    DeGregorio M; Wurz G; Emshoff V; Koester S; Minor P; Wiebe V
    Breast Cancer Res Treat; 1992; 24(1):35-41. PubMed ID: 1463870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
    Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.
    De Vincenzo R; Scambia G; Benedetti Panici P; Fattorossi A; Bonanno G; Ferlini C; Isola G; Pernisco S; Mancuso S
    Int J Cancer; 1996 Nov; 68(3):340-8. PubMed ID: 8903476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7.
    Grenman R; Laine KM; Klemi PJ; Grenman S; Hayashida DJ; Joensuu H
    J Cancer Res Clin Oncol; 1991; 117(3):223-6. PubMed ID: 1827796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of human breast cancer cell apoptosis from G2/M preceded by stimulation into the cell cycle by Z-1,1-dichloro-2,3-diphenylcyclopropane.
    Balachandran R; ter Haar E; Yalowich JC; Welsh MJ; Grant SG; Day BW
    Biochem Pharmacol; 1999 Jan; 57(1):97-110. PubMed ID: 9920290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2.
    Robinson SP; Goldstein D; Witt PL; Borden EC; Jordan VC
    Breast Cancer Res Treat; 1990 Feb; 15(2):95-101. PubMed ID: 2138919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer.
    Wiebe VJ; Benz CC; Shemano I; Cadman TB; DeGregorio MW
    Cancer Chemother Pharmacol; 1990; 25(4):247-51. PubMed ID: 2136809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13.
    Strobl JS; Peterson VA
    J Pharmacol Exp Ther; 1992 Oct; 263(1):186-93. PubMed ID: 1403784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant).
    Bouker KB; Skaar TC; Fernandez DR; O'Brien KA; Riggins RB; Cao D; Clarke R
    Cancer Res; 2004 Jun; 64(11):4030-9. PubMed ID: 15173018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance.
    Schoenlein PV; Periyasamy-Thandavan S; Samaddar JS; Jackson WH; Barrett JT
    Autophagy; 2009 Apr; 5(3):400-3. PubMed ID: 19221464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.
    Reddel RR; Sutherland RL
    Cancer Res; 1987 Oct; 47(20):5323-9. PubMed ID: 3652038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of toremifene and its main metabolites on growth of breast cancer cell lines.
    Coradini D; Biffi A; Cappelletti V; Di Fronzo G
    Anticancer Res; 1991; 11(6):2191-7. PubMed ID: 1837981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
    Reddel RR; Murphy LC; Hall RE; Sutherland RL
    Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting chemosensitizing doses of toremifene based on protein binding.
    Wurz GT; Emshoff VD; DeGregorio MW; Wiebe VJ
    Cancer Chemother Pharmacol; 1993; 31(5):412-4. PubMed ID: 8431976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.